The African meningitis belt is the area of Africa south of the Sahara that extends from Senegal in the west to Ethiopia in the east that periodically experiences acute or purulent bacterial meningitis [1] [2] [3] . These purulent meningitises are mainly caused by three etiological agents, Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis, and are characterised by a predominantly neutrophilic leukocytosis [4] [5] . Therefore, these pathogens cause meningitis epidemics especially in the meningitis belt of Lapeyssonia [1] [6] . Furthermore, these meningitis epidemics are always accompanied by high mortality and morbidity rates [1] [4] [7] .

Burkina Faso, a country located in the heart of West Africa, regularly records cases of acute bacterial meningitis [5] [7] [8] . As part of its strategy to reduce meningitis cases, Burkina Faso introduced vaccines such as the Haemophilus influenzae type b vaccine in January 2006, MenAfriVac^® in December 2010 and PCV-13 in October 2013 [7] [8] [9] . The recently introduced PCV-13 significantly reduces the occurrence of meningitis and other pneumococcal infections in relevant targets [8] [9] . As part of an overall strategy to monitor the actions of this vaccination campaign, the World Health Organization and Burkina Faso’s partners have supported the relevant departments of the Ministry of Health in moving from enhanced surveillance to case-by-case surveillance. Indeed, case-by-case surveillance is fundamentally different from enhanced surveillance because any suspected case of meningitis must be subject to a cerebrospinal fluid (CSF) sample that is analysed to identify the microorganisms involved, including pneumococci [5] [8] [9] .

S. pneumoniae occurs as gram-positive, candle-flame lanceolate diplococci and is strongly implicated in purulent and fatal meningitis due to its capsule [1] [8] [10] . This pneumococcal capsule is the source of a wide variety of serotypes that may or may not be vaccine serotypes [5] [8] [9] . The vaccine serotypes included in the pneumococcal conjugate vaccine (PCV13) are serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F [5] [8] . Non-vaccine serotypes include serogroup 12F/12A/12B/44/46, serotypes 35B, 25F and 2. The serotypes also contain several standard sequences that are important for epidemiological surveillance [11] [12] . Indeed, the determination of the different serotypes before the introduction of PCV-13 provided the government of Burkina Faso with scientific data to defend to World health organization (WHO) and its technical partners the interest of introducing PCV-13 and not pneumococcal conjugate vaccine seven valent (PCV7) or PCV10 [5] [8] [9] . Therefore, it is also important to have information on S. pneumoniae standard sequences (ST) from the same period. It is in this context that we propose to describe the type sequences of pneumococcal strains circulating in Burkina Faso before the introduction of PCV-13 in Burkina Faso.

The 37 S. pneumoniae strains were from the Centre (31.3%), East (28.1%), Centre-West (18.8%), North (12.5%), Centre-North (6.3%) and Centre-South (3.1%) regions. The youngest patient was 1 month old while the oldest was 55 years old. Of all the S. pneumoniae strains tested, 10 different serotypes were identified. Serotype 1 was the most common at 48.6% (18/37), followed by serotype 25F at 10.8% (4/37). Serotypes 5 and 12F/12A/12B/44/46 were 8.1% (3/37) each. Serotypes 4, 6B and 23F were 5.4% (2/37) each while serotypes 2, 14 and 35B were 2.7% (1/37) each. Table 2 gives the description of the different STs of the identified serotypes according to the 7 genes tested.

After the description of pneumococcal STs according the 7 genes used in MLST sequencing, it’s suitable to have more details of the proportion each ST described. Thus, the main ST described is ST303 of serotype 1 for 24.3% followed by ST105 of serotype 25F for 10.8%. Table 3 below gives for each serotype, the corresponding ST.

The cases of S. pneumoniae meningitis that occurred in Burkina Faso before the introduction of PCV13 were due to a variety of serotypes. Thus, from Table 2, we were able to determine 10 different serotypes in the present study. From Table 3, we notice a single serotype may consist of one or more STs. This is the case for serotype 1, which is made up of 5 STs, with ST303 (9/17), ST217 (3/17) and ST618 (3/17) in the foreground. Results from other work in West Africa show a high prevalence of ST303 (7/9) within serotype 1 (1). This differs from previous work in the West African region which reported ST618 as 72.7% (92/127) [11] [15] . In contrast, in South Africa, serotype 1 ST217 is reported at 96% (872/912) with three subclasses ST217 C1 at 92% (353/382), ST217C2 at 4% (15/382) and ST217C3 at 4% (14/382) [16] . Moreover, within this same serotype, there are various STs such as ST1316, ST2830, ST12695. These data show that there is great genetic diversity of pneumococcal strains circulating within the same country, from one country to another in the West African sub-region; and this, in time and space. This great genetic diversity could be explained by mutations in pneumococcal specie [16] [17] [18] .

Nevertheless, a certain homogeneity is observed in our work for non-dominant serotypes such as 25F which contains only ST105 (4/4), serotype 5 with ST289 (3/3) and serogroup 12F/12A/12B/44/46 with ST 989 (3/3). In contrast, in North America, within serogroup 12F/12A/12B/44/46, the ST218 clonal complex is reported to be the most involved in meningitis epidemics [12] . Thus, the diversity of STs of the same serotype from one continent to another could also be seen. Also, many other serotypes, such as 6B, 4, 2 and 14, yielded only one ST due to the limited number of strains. Such results do not allow any consistent conclusions to be drawn. In this context, it seems very difficult to fight against pneumococcal meningitis worldwide without laboratories diagnosis. Thus, the surveillance of these serotypes and STs could be an opportunity in the use of data for the introduction of new vaccines.

At the end of this work, we note the following limitations. Firstly, the limited number of sequenced pneumococcal strains per region does not allow us to have a distribution of ST. Secondly, it should be remembered that Burkina Faso has 13 regions, whereas we did this work with strains from 6 regions. Thirdly, the data date from 2013-2014, and may not correspond to the current situation.

However, the data reported in this study provide a basis for future work on molecular surveillance of meningitis and the impact of vaccination on the distribution of different serotypes of S. pneumoniae. Also, they reinforce the need to increase and extend the possibilities of culture of pneumococcal strains in bacteriology laboratories in our country for a better surveillance of the epidemiological profile of meningitis.

The aim of this work was to describe the typical sequences of S. pneumoniae strains in Burkina Faso. Indeed, pneumococci are characterised by their great variability in terms of both the number of serotypes and the typical sequences within the same serotype. Thus, out of all the strains, ten serotypes have been identified. Also, within serotype 1, five different standard sequences have been described.

This information gives an idea of the complexity of this pathogen which is greatly involved in purulent bacterial meningitis at both national and sub-regional levels. Preventive measures such as vaccination should be encouraged to protect the vulnerable segments of our society such as children under five years of age as well as people over sixty years of age.

This also requires continuous surveillance of pneumococcal meningitis, which requires laboratory capacity building and staff training.

At the end of this work, we thank the Ministry of Health through its technical structures such as the Directorate of Population Health Protection (DPSP). We also thank our partners at CDC-Atlanta in Georgia, USA, particularly Dr. McGee Lesley, Dr. Srinivassan and Dr. Mahamoudou Ouattara.

Conceptualization: KD, OTR, SL

Data curation: KD, TM, TI

Formal analysis: KD, OTR, ZAA, OO

Investigation: KD, SM, OTR

Resources: OTR, AF, MI

Supervision: OTR, KS, MI

Validation: OWHG, ZAA,

Visualization: OTR, KD, ASO

Writing ± original draft: KD, ASO, KBA

Writing ± review & editing: OO, CR, ST, ZS, SRST

The authors declare no conflicts of interest regarding the publication of this paper.

Dinanibè, K., Mamadou, T., Oumarou, O., Issa, T., Gautier, O.W.H., Mahamoudou, S., Azaque, Z.A., Rebeca, C., Tani, S., Théophile, S.R.S., Sylvie, Z., Flavien, A., Ouédraogo, A.-S., Lassana, S., Isaïe, M., Séni, K. and Rasmata, O.-T. (2023) ST of Streptococcus pneumoniae Circulating in Burkina Faso before the Introduction of PCV-13, 2013. Advances in Microbiology, 13, 237-248. https://doi.org/10.4236/aim.2023.135015